BOULDER, Colo.--(BUSINESS WIRE)--Sept. 7, 2006--BaroFold, Inc. announced today the granting of a research license to Genentech, Inc. (NYSE:DNA) for BaroFold’s proprietary PreEMT(TM) high pressure technology for solubilizing, disaggregating and refolding proteins under a previously executed service and license agreement. The license agreement enables Genentech to utilize BaroFold’s patented technology and instrumentation for research, and grants Genentech an option to trigger a commercial license. Up-front payment, milestones and other financial terms were not disclosed. Genentech joins several other biotechnology firms and pharmaceutical corporations who have collaborated with BaroFold to refold and produce proteins.
